214 related articles for article (PubMed ID: 30697447)
1. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report.
Nassri AB; Muenyi V; AlKhasawneh A; Ribeiro BS; Scolapio JS; Malespin M; de Melo SW
World J Gastrointest Pharmacol Ther; 2019 Jan; 10(1):29-34. PubMed ID: 30697447
[TBL] [Abstract][Full Text] [Related]
2. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
3. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.
Merrill SP; Reynolds P; Kalra A; Biehl J; Vandivier RW; Mueller SW
Ann Pharmacother; 2014 Jun; 48(6):806-10. PubMed ID: 24651165
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma.
Moein HR; Rutledge B; Beydoun R; Ehrinpreis MN
Cureus; 2021 Apr; 13(4):e14414. PubMed ID: 33987063
[TBL] [Abstract][Full Text] [Related]
5. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
6. A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids.
Alcantar D; Al-Jaashaami L; Giron F
Cureus; 2019 Dec; 11(12):e6392. PubMed ID: 31938669
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report.
Randhawa M; Gaughran G; Archer C; Pavli P; Morey A; Ali S; Yip D
World J Clin Oncol; 2019 Oct; 10(10):350-357. PubMed ID: 31799150
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation.
Shah R; Witt D; Asif T; Mir FF
Cureus; 2017 Apr; 9(4):e1182. PubMed ID: 28533998
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for ipilimumab-induced colitis: A series of 13 patients.
Hillock NT; Heard S; Kichenadasse G; Hill CL; Andrews J
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e284-e290. PubMed ID: 27981760
[TBL] [Abstract][Full Text] [Related]
11. Multiorgan Failure From Nivolumab and Ipilimumab: A Case Report and Literature Review.
Brazel D; Lee S; Mahadevan A; Warnecke B; Parajuli R
Cureus; 2023 Jul; 15(7):e41781. PubMed ID: 37575835
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
Kaneoka A; Okada E; Sugino H; Saito-Sasaki N; Omoto D; Nakamura M
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204571
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab-Induced Enteritis without Colitis: A New Challenge.
Messmer M; Upreti S; Tarabishy Y; Mazumder N; Chowdhury R; Yarchoan M; Holdhoff M
Case Rep Oncol; 2016; 9(3):705-713. PubMed ID: 27920706
[TBL] [Abstract][Full Text] [Related]
14. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Immune Checkpoint Inhibitor Induced Colitis with Infliximab.
Tidwell C; Gutnik S
S D Med; 2019 Oct; 72(10):454-458. PubMed ID: 31816206
[TBL] [Abstract][Full Text] [Related]
17. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594
[TBL] [Abstract][Full Text] [Related]
18. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
Minor DR; Chin K; Kashani-Sabet M
Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma.
Paparoupa M; Stupperich S; Goerg-Reifenberg L; Wittig A; Schuppert F
Case Rep Gastroenterol; 2020; 14(3):554-560. PubMed ID: 33250697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
